Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)

  1. De Laurentiis, M.
  2. Borstnar, S.
  3. Campone, M.
  4. Warner, E.
  5. Bofill, J.S.
  6. Jacot, W.
  7. Dent, S.
  8. Martin, M.
  9. Ring, A.
  10. Cottu, P.
  11. Lu, J.
  12. Ciruelos, E.
  13. Azim, H.A.
  14. Chatterjee, S.
  15. Zhou, K.
  16. Wu, J.
  17. Menon-Singh, L.
  18. Zamagni, C.
Aldizkaria:
Breast Cancer Research and Treatment

ISSN: 1573-7217,  0167-6806

Argitalpen urtea: 2022

Alea: 191

Zenbakia: 1

Orrialdeak: 223-224

Mota: Hutsen zuzenketa

DOI: 10.1007/S10549-021-06374-6 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus